Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.02
NAS:NKTR's Cash to Debt is ranked lower than
80% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. NAS:NKTR: 1.02 )
Ranked among companies with meaningful Cash to Debt only.
NAS:NKTR' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1.43 Max: 389.59
Current: 1.02
0.72
389.59
Equity to Asset -0.16
NAS:NKTR's Equity to Asset is ranked lower than
94% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:NKTR: -0.16 )
Ranked among companies with meaningful Equity to Asset only.
NAS:NKTR' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.32 Max: 0.87
Current: -0.16
-0.21
0.87
F-Score: 2
Z-Score: -4.25
M-Score: 1.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -65.77
NAS:NKTR's Operating margin (%) is ranked higher than
53% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. NAS:NKTR: -65.77 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:NKTR' s Operating margin (%) Range Over the Past 10 Years
Min: -173.91  Med: -76.91 Max: -8.21
Current: -65.77
-173.91
-8.21
Net-margin (%) -98.87
NAS:NKTR's Net-margin (%) is ranked lower than
53% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:NKTR: -98.87 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:NKTR' s Net-margin (%) Range Over the Past 10 Years
Min: -211.67  Med: -54.58 Max: -12
Current: -98.87
-211.67
-12
ROA (%) -35.54
NAS:NKTR's ROA (%) is ranked lower than
55% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. NAS:NKTR: -35.54 )
Ranked among companies with meaningful ROA (%) only.
NAS:NKTR' s ROA (%) Range Over the Past 10 Years
Min: -35.54  Med: -17.66 Max: -4.39
Current: -35.54
-35.54
-4.39
ROC (Joel Greenblatt) (%) -176.00
NAS:NKTR's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:NKTR: -176.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:NKTR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -182.91  Med: -75.33 Max: -9.76
Current: -176
-182.91
-9.76
Revenue Growth (3Y)(%) 35.10
NAS:NKTR's Revenue Growth (3Y)(%) is ranked higher than
84% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:NKTR: 35.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:NKTR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.6  Med: 8.4 Max: 58.7
Current: 35.1
-31.6
58.7
EBITDA Growth (3Y)(%) -41.20
NAS:NKTR's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:NKTR: -41.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:NKTR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.5  Med: 9.6 Max: 109.1
Current: -41.2
-71.5
109.1
EPS Growth (3Y)(%) -25.90
NAS:NKTR's EPS Growth (3Y)(%) is ranked lower than
76% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:NKTR: -25.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:NKTR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.4  Med: 3.6 Max: 100.4
Current: -25.9
-44.4
100.4
GuruFocus has detected 4 Warning Signs with Nektar Therapeutics Inc $NAS:NKTR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:NKTR's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

NKTR Guru Trades in Q4 2015

PRIMECAP Management 19,784,286 sh (+0.20%)
Steven Cohen 17,500 sh (-87.27%)
» More
Q1 2016

NKTR Guru Trades in Q1 2016

Paul Tudor Jones 13,700 sh (New)
PRIMECAP Management 20,010,086 sh (+1.14%)
Steven Cohen 9,200 sh (-47.43%)
» More
Q2 2016

NKTR Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
PRIMECAP Management 20,002,586 sh (-0.04%)
» More
Q3 2016

NKTR Guru Trades in Q3 2016

Stanley Druckenmiller 572,100 sh (New)
PRIMECAP Management 20,006,621 sh (+0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SRPT, NAS:AGIO, NAS:ONCE, NAS:ARRY, NYSE:CBM, NAS:PRTA, NAS:SAGE, OTCPK:ABCZF, NAS:DBVT, NAS:FGEN, NAS:TBPH, NAS:JUNO, NAS:LGND, NAS:HALO, NAS:FWP, NAS:LXRX, NAS:AVXS, NAS:PTLA, OTCPK:MPSYY, NAS:KITE » details
Traded in other countries:ITH.Germany,
Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to develop molecular entities.

Nektar Therapeutics Inc was incorporated in July 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its drug candidates by using its proprietary polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company also has a collaboration with Bayer Healthcare LLC "Bayer" to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. Bayer has initiated a Phase 3 clinical development of BAY41-6551 with the first patient enrolled in April 2013. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change freque.

Ratios

vs
industry
vs
history
P/S 9.72
NKTR's P/S is ranked higher than
53% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. NKTR: 9.72 )
Ranked among companies with meaningful P/S only.
NKTR' s P/S Range Over the Past 10 Years
Min: 1.76  Med: 8.81 Max: 16.57
Current: 9.72
1.76
16.57
Current Ratio 3.70
NKTR's Current Ratio is ranked lower than
54% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. NKTR: 3.70 )
Ranked among companies with meaningful Current Ratio only.
NKTR' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 5.79 Max: 16.32
Current: 3.7
1
16.32
Quick Ratio 3.56
NKTR's Quick Ratio is ranked lower than
53% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. NKTR: 3.56 )
Ranked among companies with meaningful Quick Ratio only.
NKTR' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.69 Max: 16.32
Current: 3.56
0.96
16.32
Days Inventory 123.20
NKTR's Days Inventory is ranked higher than
51% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. NKTR: 123.20 )
Ranked among companies with meaningful Days Inventory only.
NKTR' s Days Inventory Range Over the Past 10 Years
Min: 33.21  Med: 121.03 Max: 185.48
Current: 123.2
33.21
185.48
Days Sales Outstanding 31.08
NKTR's Days Sales Outstanding is ranked higher than
75% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. NKTR: 31.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
NKTR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.46  Med: 27.52 Max: 79.04
Current: 31.08
5.46
79.04
Days Payable 81.25
NKTR's Days Payable is ranked higher than
63% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. NKTR: 81.25 )
Ranked among companies with meaningful Days Payable only.
NKTR' s Days Payable Range Over the Past 10 Years
Min: 8.88  Med: 35.37 Max: 144.1
Current: 81.25
8.88
144.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.50
NKTR's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. NKTR: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NKTR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -7.3 Max: -0.7
Current: -5.5
-17.6
-0.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.11
NKTR's Price/Median PS Value is ranked lower than
63% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. NKTR: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
NKTR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.15 Max: 4.84
Current: 1.11
0.22
4.84
Earnings Yield (Greenblatt) (%) -6.90
NKTR's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. NKTR: -6.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NKTR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.9  Med: 3.6 Max: 4.9
Current: -6.9
-6.9
4.9

More Statistics

Revenue (TTM) (Mil) $167.4
EPS (TTM) $ -1.22
Beta1.98
Short Percentage of Float12.41%
52-Week Range $10.52 - 19.98
Shares Outstanding (Mil)152.84

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 168 203 233 267
EPS ($) -1.02 -0.58 -0.46 -0.33
EPS w/o NRI ($) -1.02 -0.58 -0.46 -0.33
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:NKTR

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Monolithic Power Systems, Five Prime Therapeutics, Nektar Therapeutics Feb 15 2016 
Weekly CEO Sells Highlight: Cadence Design Systems Inc., Nektar Therapeutics Inc., Netflix Inc., Pho Sep 27 2015 
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 

More From Other Websites
NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Jan 10 2017
Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017 Jan 06 2017
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan... Jan 05 2017
Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5,... Jan 05 2017
ETFs with exposure to Nektar Therapeutics : December 27, 2016 Dec 27 2016
Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings Dec 27 2016
ETFs with exposure to Nektar Therapeutics : December 16, 2016 Dec 16 2016
These small-cap stocks are expected to rise at least 31% in 2017 Dec 09 2016
ETFs with exposure to Nektar Therapeutics : December 6, 2016 Dec 06 2016
Is The New York Times Co (NYT) A Good Stock To Buy? Nov 28 2016
ETFs with exposure to Nektar Therapeutics : November 14, 2016 Nov 14 2016
Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London Nov 14 2016
NEKTAR THERAPEUTICS Financials Nov 11 2016
Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of... Nov 09 2016
NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events Nov 09 2016
Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss Nov 08 2016
Coverage initiated on Nektar Therapeutics by Aegis Capital Nov 08 2016
Cormorant Asset Management’s Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare... Nov 07 2016
Edited Transcript of NKTR earnings conference call or presentation 3-Nov-16 9:00pm GMT Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)